Frontlight ResearchEarly access
Myeloproliferative neoplasms trials in Belgium
15 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Where
- Antwerp, Roeselare, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00 - Phase 1Not yet taking people in BelgiumStudy of INCA036978 in Participants With Myeloproliferative Neoplasms
- Where
- Liège, Roeselare
- Age
- 18 years and over
- People
- 218 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07441694 · EU 2026-525217-31-00 - Phase 3Not yet taking people in BelgiumA Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- Where
- Anderlecht, Brussels, Leuven, Liège, Roeselare, Woluwe-Saint-Lambert
- Age
- 18 years and over
- People
- 426 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00 - Phase 3Not yet taking people in BelgiumA Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Where
- Antwerp, La Louvière, Leuven, Roeselare, Yvoir
- Age
- 18 years and over
- People
- 324 worldwide
- Run by
- Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00 - Phase 1/2Taking peopleA Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Where
- Antwerp, Gent, Leuven, Liège
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00 - Phase 2Active, not recruitingA Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
- Where
- Gent, Leuven
- Age
- 18 years and over
- People
- 38 worldwide
- Run by
- Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 - Phase 2Withdrawn(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Liège
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - Phase 3Taking peopleAdding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
- Where
- Antwerp, Leuven, Liège, Roeselare, Yvoir
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 - Phase 1Not yet taking people in BelgiumA Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Where
- Brussels, Ghent, Leuven
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07008118 - Phase 3CompletedA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Brasschaat, Bruges, Ghent, Leuven
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - No phaseTaking peopleIdentification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
- Where
- Brussels
- Age
- 18 years and over
- People
- 150
- Run by
- Université Catholique de Louvain
See details and how to joinNCT07590986 - Phase 2Taking peopleA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Where
- Ghent, Leuven
- Age
- 18 years and over
- People
- 58 worldwide
- Run by
- Karyopharm Therapeutics Inc
See details and how to joinNCT05980806 - Phase 3Taking peopleAn extension study for patients previously enrolled in studies with pelabresib
- Where
- Antwerp, Brugge
- Age
- 18 years and over
- People
- 34 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT06401356 · EU 2023-508950-24-00 - Phase 3Taking peopleStudy of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Where
- Antwerp, Leuven, Liège, Roeselare, Yvoir
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT06479135 - Phase 2Taking peopleAllogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
- Where
- Anderlecht, Antwerp, Brugge, Gent, Jette, Leuven, Roeselare, Sint-Lambrechts-Woluwe, Yvoir
- Age
- 18 years to 75 years
- People
- 114
- Run by
- University of Liege
See details and how to joinNCT03852407 · EU 2024-518568-11-00